MetaCap

Boston Scientific (BSX) vs ResMed (RMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ResMed (RMD) has outperformed Boston Scientific (BSX) over the past year, losing 6.0% versus a loss of 56.7%. Over five years, BSX leads with a +8.8% price change compared with -6.2% for RMD. Boston Scientific is the larger company by market cap ($60.85 billion vs $33.14 billion), about 1.8 times the size.

On valuation, Boston Scientific trades at a lower forward P/E (13.4x vs 17.8x for ResMed). ResMed pays a dividend yielding 1.04%, while Boston Scientific does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 14.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSX-56.67%RMD-6.03%
+13%-24%-60%
Nov 21, 20251 yearNov 20, 2026
BSX+2.32%RMD-9.48%
+172%+57%-59%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSX versus RMD key metrics
MetricBSXRMD
Share price$41.98$235.63
Market cap$60.85B$33.14B
1-day change-2.35%-0.53%
YTD return-55.97%-2.18%
1-year return-56.67%-6.03%
5-year return+8.84%-6.20%
P/E ratio (TTM)17.7121.46
Forward P/E13.4117.82
EPS (TTM)$2.37$10.98
Dividend yield0.00%1.04%
Annual dividend$0.00$2.46
Revenue (latest FY)$20.07B$5.65B
Revenue growth (YoY)+19.87%+9.85%
Net income (latest FY)$2.89B$1.52B
Gross margin69.01%61.06%
Operating margin18.00%33.37%
Net margin14.41%26.94%
52-week high$101.91$277.67
52-week low$39.57$180.27
Distance from 52-week high-58.81%-15.14%
Analyst consensusbuybuy
Avg. price target upside+18.15%+12.18%
Average volume19.19M1.30M
Shares outstanding1.45B140.66M
Employees59,00011,370
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RMD has outperformed BSX by 50.6 percentage points over the past year.
  • ResMed offers a meaningfully higher dividend yield (1.04% vs 0.00%).
  • ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 14.4 cents for Boston Scientific.
  • Boston Scientific grew revenue faster in its latest fiscal year (+19.87% vs +9.85%).

About Boston Scientific

BSX stock →

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Health Care · Medical/Dental Instruments · 59,000 employees

About ResMed

RMD stock →

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.

Health Care · Medical/Dental Instruments · 11,370 employees

BSX vs RMD FAQ

Which is bigger, Boston Scientific or ResMed?

Boston Scientific (BSX) is larger, with a market capitalization of $60.85B compared with $33.14B for ResMed (RMD).

Which stock has performed better over the past year, BSX or RMD?

RMD returned -6.03% over the past 12 months, compared with -56.67% for BSX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BSX or RMD?

BSX has the lower trailing P/E at 17.7, versus 21.5 for RMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Boston Scientific or ResMed?

ResMed pays a dividend yielding 1.04%, while Boston Scientific does not currently pay a regular dividend.

Are Boston Scientific and ResMed in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons